Study Indicates Approved Ebola Antibody May Be Ineffective Against Current Bundibugyo Virus Outbreak

A *Nature Communications* study suggests that mAb114, an FDA-approved Ebola treatment, may not effectively target the Bundibugyo virus (BDBV) driving the 2026 outbreak in Central and East Africa. Genetic divergence and novel mutations in BDBV's glycoprotein could render the antibody ineffective. This research underscores the urgent need to test existing treatments specifically against BDBV to ensure their efficacy in the ongoing outbreak.